| abstract |
The present invention relates to the use of a mutant polypeptide β-chain of the interferon receptor type I (IFNAR2) (MIFNAR2), having the amino acid sequence SEQ ID NO: 1, mutated at 78 amino acid residues of histidine at position 78 and asparagine at position 100, having increased affinity for interferon- β (IFN-β) compared with the wild-type polypeptide, or an analogue of the mutant polypeptide, having essentially the same activity, which up to 30 amino acid residues can be removed, added or substituted, with Words that these residues are not residues 78 and 100, or a salt thereof, for the manufacture of a medicament modulating the effects of IFN-β. The invention also relates to a pharmaceutical composition comprising said polypeptide. |